Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

Please provide your email address to receive an email when new articles are posted on . Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those ...

Please provide your email address to receive an email when new articles are posted on . Patients who achieved enthesitis resolution were more likely to have improvements in pain and physical function.

Around 5% of patients treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis experience musculoskeletal (MSK) symptoms, according to the results of a descriptive study. The main ...

Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of ...

Ixekizumab demonstrates strong response rates in juvenile arthritis. Read more about the latest trial findings.

Basel, December 22, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) for the treatment ...

GRAPPA published treatment recommendations for PsA in 2009 based on evidence from systematic reviews and consensus of 70 rheumatologists and dermatologists with subspecialty expertise in management of ...

The monoclonal antibody guselkumab (Tremfya), which targets the p19 subunit of interleukin (IL)-23, was effective for treating the enthesitis and dactylitis components of psoriatic arthritis (PsA), ...

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found. At week 24, 45% of patients ...

Spondyloarthritis (SpA) refers to a spectrum of immune-mediated inflammatory diseases with overlapping features, which differ from other types of inflammatory arthritis in genetic predisposition, ...

Basel, December 22, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) for the treatment ...